Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: A report from the Children's Cancer Group

Cancer

Volumn 83, Issue 9, 1998, Pages 2030-2039

  Uckun, Fatih M ^a,l   Nachman, James B ^b   Sather, Harland N ^c,d   Sensel, Martha G ^d   Kraft, Peter ^e   Steinherz, Peter G ^f   Lange, Beverly ^g   Hutchinson, Raymond ^h   Reaman, Gregory H ⁱ   Gaynon, Paul S ^j   Heerema, Nyla A ^k  

^a PARKER HUGHES INSTITUTE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ GEORGE WASHINGTON UNIVERSITY   (United States)

^j UNIVERSITY OF WISCONSIN MADISON   (United States)

^k INDIANA UNIVERSITY   (United States)

^l The Leukemia & Lymphoma Society   (United States)

more..

Author keywords

Acute lymphoblastic leukemia; Children; Cytogenetics; Philadelphia chromosome

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE; ARTICLE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; CYTOGENETICS; FEMALE; HUMAN; HUMAN CELL; INFANT; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; RACE; RISK FACTOR; TREATMENT OUTCOME;

BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; RISK ADJUSTMENT; RISK FACTORS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 0032212447     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981101)83:9<2030::AID-CNCR21>3.0.CO;2-Q     Document Type: Article

References (37)

1. Nowell P, Hungerford D. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85.
2. Rowley J. Ph-positive leukaemia, including chronic myelogenous leukaemia. Clin Haematol 1980;9:55.
3. Fletcher JA, Lynch EA, Kimball VM, Donnelly M, Tantravahi R, Sallan SE. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 1991;77(3):435-9.
4. Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. a Pediatric Oncology Group study. Blood 1990;76(3):489-94.
5. Ribeiro RC, Abromowitch M, Raimondi SC, Murphy SB, Behm F, Williams DL. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 1987;70(4):948-53.
6. Hermans A, Heisterkamp N, von Linden M, van Baal S, Meijer D, van der Plas D, et al. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987;51(1):33-40.
7. Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 1987;235(4784):85-8.
8. Hooberman AL, Carrino JJ, Leibowitz D, et al. Unexpected heterogeneity of Bcr-Abl fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1989;86(11):4259-63.
9. Ribeiro R, Broniscer A, Rivera G, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts. Leukemia 1997;11(9):1493-6.
10. Arico M, Schrappe M, Harbott J, et al. Prednisone good response (PGR) identifies a subset of t(9;22) childhood acute lymphoblastic leukemia (AL) at lower risk for early leukemia relapse. Blood 1997;10:560a.
11. Roberts W, Rivera G, Raimondi S, et al. Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Lancet 1994;343:331-2.
12. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia [see comments]. J Clin Oncol 1996;14(1):18-24.
13. Steinherz PG, Siegel SE, Bleyer WA, et al. Lymphomatous presentation of childhood acute lymphoblastic leukemia. Cancer 1991;68:751-8.
14. Heerema NA, Palmer CG, Baehner RL. Karyotypic and clinical findings in a consecutive series of children with acute lymphocytic leukemia. Cancer Genet Cytogenet 1985;17(2):165-79.
15. Mitelman F. ISCN: an international system for human cytogenetic nomenclature. Basel, Switzwerland: Karger, 1995.
16. Uckun FM, Muraguchi A, Ledbetter JA, et al. Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood 1989;73(4):1000-15.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
19. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1.
20. Nachman I, Sather H, Cherlow I, Sensel MG, Gaynon PS, Lukens JN et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol 1998;16:920-30.
21. Westbrook C, Hooberman A, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a cancer and leukemia Group B study (8762). Blood 1992;80:2983-90.
22. Dow LW, Tachibana N, Raimondi SC, Lauer SJ, Witte ON, Clark SS. Comparative biochemical and cytogenetic studies of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and other 22q 11 variants. Blood 1989;73(5):1291-7.
23. Russo C, Carroll A, Kohler S, et al. Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 1991;77(5):1050-6.
24. Chilcote RR, Brown E, Rowley JD. Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9. N Eng J Med 1985;313:286-91.
25. Raimondi SC, Behm FG, Roberson PK, et al. Cytogenetics of childhood T-cell leukemia. Blood 1988;72(5):1560-6.
26. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991;337(8733):61-6.
27. Uckun F, Reaman G, Steinherz P, et al. Improved outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group study. Leuk Lymphoma 1996;24:57-70.
28. Altman A, Steinherz P, Trigg M, et al. A prospective randomized trial of granulocyte colony-stimulating factor (G-CSF) during induction or consolidation phases of intensive chemotherapy for acute lymphocytic leukemia (ALL) [meeting abstract]. J Clin Oncol 1996;15.
29. Nachman J, Sather HN, Gaynon PS, Lukens JN, Wolff L, Trigg ME. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Onol 1997;15:2222-30.
30. Uckun F, Sensel M, Sather H, et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 1997;16:527-35.
31. + immature B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma 1997;27:445-57.
32. Sierra J, Radich J, Hansen JA, et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997;90(4):1410-4.
33. Carlo Stella C, Dotti G, Mangoni L, et al. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood 1996;88(8):3091-100.
34. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2(5):561-6.
35. Honma Y, Matsuo Y, Hayashi Y, Omura S. Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor. Int J Cancer 1995;60(5):685-8.
36. Uckun FM, Evans WE, Forsyth CJ, et al. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 1995;267(5199):886-91.
37. Skorski T, Nieborowska Skorska M, Wlodarski P, et al. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides [see comments]. J Natl Cancer Inst 1997;89(2):124-33.